166 related articles for article (PubMed ID: 1702493)
61. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.
Feld R; Rubinstein L; Thomas PA
J Natl Cancer Inst; 1993 Feb; 85(4):299-306. PubMed ID: 8381187
[TBL] [Abstract][Full Text] [Related]
62. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
[TBL] [Abstract][Full Text] [Related]
63. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
64. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
65. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
Rosell R; Gómez-Codina J; Camps C; Maestre J; Padille J; Cantó A; Mate JL; Li S; Roig J; Olazábal A
N Engl J Med; 1994 Jan; 330(3):153-8. PubMed ID: 8043059
[TBL] [Abstract][Full Text] [Related]
66. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy.
Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Miya T; Okamoto H; Iemura K
Cancer Chemother Pharmacol; 1992; 30(1):1-6. PubMed ID: 1316809
[TBL] [Abstract][Full Text] [Related]
67. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
68. [Combination of cisplatin-mitomycin-vindesine for inoperable, non-small-cell bronchial cancers. French study group in pneumo-cancerology].
Kleisbauer JP; Thomas P; Perol M; Taytard A; Poirier R; Collus MJ; Guerin JC; Vergnenegre A; Balmes P; Carles P
Rev Mal Respir; 1993; 10(4):307-12. PubMed ID: 7694331
[TBL] [Abstract][Full Text] [Related]
69. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.
Le Chevalier T; Arriagada R; Quoix E; Ruffie P; Martin M; Douillard JY; Tarayre M; Lacombe-Terrier MJ; Laplanche A
Lung Cancer; 1994 Mar; 10 Suppl 1():S239-44. PubMed ID: 8087515
[TBL] [Abstract][Full Text] [Related]
70. [The value of carcinoembryonic antigens in patients with advanced lung cancer: in relation to chemotherapy].
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Takahashi K; Sasaki Y; Ohkura H
Gan To Kagaku Ryoho; 1984 May; 11(5):1056-63. PubMed ID: 6202246
[TBL] [Abstract][Full Text] [Related]
71. Histopathological grading of response to induction chemotherapy in non-small cell lung cancer: a preliminary study.
Milano S; Zorzi F; Marini G; Zaniboni A; Ottoni DB; Di Fabio D; Mombelloni G
Lung Cancer; 1996 Sep; 15(2):183-7. PubMed ID: 8882984
[TBL] [Abstract][Full Text] [Related]
72. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
Pisters KM; Kris MG; Gralla RJ; Zaman MB; Heelan RT; Martini N
J Clin Oncol; 1993 Sep; 11(9):1757-62. PubMed ID: 8394881
[TBL] [Abstract][Full Text] [Related]
73. Induction chemotherapy in non small cell lung cancer stage IIIa-b and IV and second-line treatment.
Stathopoulos GP; Dafni UG; Malamos NA; Rigatos S; Kouvatseas G; Moschopoulos N
Anticancer Res; 1999; 19(4C):3543-8. PubMed ID: 10629650
[TBL] [Abstract][Full Text] [Related]
74. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
[TBL] [Abstract][Full Text] [Related]
75. Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
Lele SB; Piver MS
Gynecol Oncol; 1989 Apr; 33(1):6-8. PubMed ID: 2467845
[TBL] [Abstract][Full Text] [Related]
76. The benefit of cisplatin-based polychemotherapy for adenocarcinoma of the lung. The Kyushu Lung Cancer Chemotherapy Study Group.
Hara N; Ohta M; Ichikawa Y; Kanda T; Shima K; Tamura K; Hokama M
Cancer Chemother Pharmacol; 1990; 26(1):47-51. PubMed ID: 2108816
[TBL] [Abstract][Full Text] [Related]
77. Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future.
Bakowski MT; Crouch JC
Cancer Treat Rev; 1983 Sep; 10(3):159-72. PubMed ID: 6311415
[No Abstract] [Full Text] [Related]
78. Should chemotherapy response be evaluated separately in sequential chemotherapy-radiotherapy schedules in locally advanced nonsmall-cell lung carcinoma?
Thomas F; Le Chevalier T; Arriagada R; Ruffié P; Baldeyrou P
Antibiot Chemother (1971); 1988; 41():138-41. PubMed ID: 2854433
[No Abstract] [Full Text] [Related]
79. Induction chemotherapy for stage IIIA unresectable non-small cell lung cancer: the Toronto experience and an overview.
Goldberg M; Burkes RL
Semin Surg Oncol; 1993; 9(2):108-13. PubMed ID: 8387687
[TBL] [Abstract][Full Text] [Related]
80. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.
Keller SM; Vangel MG; Adak S; Wagner H; Schiller JH; Herskovic A; Komaki R; Perry MC; Marks RS; Livingston RB; Johnson DH
Lung Cancer; 2002 Sep; 37(3):303-9. PubMed ID: 12234700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
